Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Osteogenesis imperfecta at the beginning of bone and joint decade (CROSBI ID 93416)

Prilog u časopisu | pregledni rad (stručni)

Primorac, Dragan ; Rowe, David, W ; Mottes, Monica ; Barišić, Ingeborg ; Antičević, Darko ; Mirandola, Stefania ; Gomez Lira, Macarena ; Kalajzić, Ivo ; Kušec, Vesna ; Glorieux, Francis, H Osteogenesis imperfecta at the beginning of bone and joint decade // Croatian medical journal, 42 (2001), 4; 393-415-x

Podaci o odgovornosti

Primorac, Dragan ; Rowe, David, W ; Mottes, Monica ; Barišić, Ingeborg ; Antičević, Darko ; Mirandola, Stefania ; Gomez Lira, Macarena ; Kalajzić, Ivo ; Kušec, Vesna ; Glorieux, Francis, H

engleski

Osteogenesis imperfecta at the beginning of bone and joint decade

Osteogenesis imperfecta (OI), or brittle bone disease, is a heritable disorder characterized by increased bone fragility. Four different types of the disease are commonly distinguished, ranging from a mild condition (type I) to a lethal one (type II). Types III and IV are the severe forms surviving the neonatal period. In most cases, there is a reduction in the production of normal type I collagen or the synthesis of abnormal collagen as a result of mutations in the type I collagen genes. These � classic� forms of OI are described in this review. There are instances, however, where alterations in bone matrix components, other than type I collagen, are the basic abnormalities of the OI. Recently, three such discrete types have been identified by histomorphometric evaluation (types V and VI) and linkage analysis (Rhizomelic OI). They provide evidence for the as yet poorly understood complexity of the phenotype-genotype correlation in OI. We also discuss bisphosphonates treatment as well as fracture management and surgical correction of deformities observed in the patients with OI. However, ultimately, strengthening bone in OI will involve steps to correct the underlying genetic mutations that are responsible for this disorder. Thus, we also describe different genetic therapeutic approaches that have been tested either on OI cells or on available OI murine models.

collagen; dentinogenesis imperfecta; gene therapy; genetics; mutation; osteogenesis imperfecta; syndrome

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

42 (4)

2001.

393-415-x

objavljeno

0353-9504

Povezanost rada

Javno zdravstvo i zdravstvena zaštita

Indeksiranost